Structure Therapeutics (NASDAQ:GPCR) Shares Up 6% - Still a Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) rose 6% on Wednesday . The company traded as high as $21.99 and last traded at $22.39. Approximately 59,438 shares traded hands during trading, a decline of 93% from the average daily volume of 838,890 shares. The stock had previously closed at $21.11.

Analyst Ratings Changes

Several brokerages recently weighed in on GPCR. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price for the company. JMP Securities reissued a "market outperform" rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, William Blair began coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $81.29.

Structure Therapeutics Trading Down 4.1 %

The company has a 50 day simple moving average of $24.80 and a 200 day simple moving average of $31.75. The stock has a market cap of $1.20 billion, a P/E ratio of -28.34 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, sell-side analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Remove Ads

Institutional Trading of Structure Therapeutics

Several large investors have recently bought and sold shares of GPCR. Geode Capital Management LLC lifted its position in shares of Structure Therapeutics by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock worth $1,985,000 after purchasing an additional 312 shares during the period. Virtus ETF Advisers LLC raised its stake in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after buying an additional 455 shares during the period. ANTIPODES PARTNERS Ltd raised its position in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after purchasing an additional 553 shares during the period. LPL Financial LLC lifted its position in shares of Structure Therapeutics by 6.0% during the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock worth $311,000 after acquiring an additional 646 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in Structure Therapeutics by 12.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after purchasing an additional 843 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.